Blog

India revokes patent for Pfizer’s Sutent

India has blown another raspberry at Big Pharma. In its third strike against foreign drugmakers, the Indian patent office yanked Pfizer’s ($PFE) patent on the kidney cancer drug Sutent. The move was a victory for local drugmakers Cipla and Natco .. read more

22
Feb
posted in News by

NATCO granted compulsory licence for Nexavar

Mar 12th 2012 The Hyderabad based NATCO Pharma Limited is pleased to announce the granting of a compulsory licence to it, under the provisions of Section 84 of the Indian Patents Act, 1970 for Sorafenib Tosylate (Brand Name : Nexavar .. read more

12
Nov
posted in News by